Lantus, Insulin Glargine News

Diabetes isn't very loving, but here at the 'Mine , we're here to support you! Welcome to another edition of our weekly advice column, Ask D'Mine , hosted by veteran type 1, diabetes author and community educator Wil Dubois.

Change at Change at Q4 2011 Change on a constant 2011 Change on a constant ------- ----------- --------- ---- ----------- --------- reported reported basis exchange rates basis exchange rates --------- -------------- --------- -------------- euro euro Net sales 8,508m +8.8% +9.2% 33,389m +3.2% +5.3% Business net euro income 2,077m +13.0% +11.7% ... (more)

Sanofi said it was set to return to growth after 2012 -- a year in which sales will be hit by generic competition, as the French drugmaker met forecasts with a 13 percent rise in fourth-quarter profit.

Drugmaker Sanofi SA says its earnings rose in the fourth quarter thanks to its acquisition of U.S. biotechnology firm Genzyme as well as double-digit growth in its consumer healthcare, diabetes and emerging markets businesses.

It's not often you can take a true story based on a young man who gets cancer before slowly... Historically, patients go through three phases for control.

There have been growing concerns regarding the long-term effects of insulin glargine on the risk of breast cancer.

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.